Why the study?
Pregnancy poses significant maternal and foetal risk in women with pulmonary arterial hypertension, and treatment options are extremely limited.
Does Selexipag added to tadalafil safely manage pregnancy complicated by pulmonary arterial hypertension?
Does Selexipag added to tadalafil safely manage pregnancy complicated by pulmonary arterial hypertension?
Selexipag may be a promising add-on therapy to tadalafil for managing pregnancy complicated by pulmonary arterial hypertension.
Supports further investigation of selexipag in PAH pregnancies; hypothesis-generating and should not yet change practice.
Pregnancy poses a significant maternal and foetal risk in women with pulmonary arterial hypertension (PAH). With extremely limited treatment options available, we used Selexipag in addition to tadalafil in managing a pregnancy complicated by PAH. Selexipag may be a promising add-on therapy in this unique subset.
No takes yet. Share an insight, caveat, or question.
Mohanty et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: